Business context and reporting period
The supplied filing is Trxade Group, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 23, 2015. This does not match the request metadata naming Scienture Holdings, Inc.; verify the issuer before relying on this summary. Trxade operated a business-to-business pharmaceutical marketplace, a pharmaceutical wholesaler, and an IT consulting business. The platform connected independent pharmacies and suppliers; the company also offered pharmacy data and pricing tools, some of which had not generated revenue.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $1,496,227 | $955,881 |
| Gross profit | $1,056,180 | $11,811 |
| Gross margin | 70.6% | 1.2% |
| Operating loss | $(1,431,472) | $(2,084,004) |
| Net loss | $(2,012,043) | $(2,091,285) |
| Cash used in operations | Approximately $(1,064,576) | $(844,579) |
Revenue rose approximately 56.5%. The filing attributes the increase and improved gross profit primarily to greater platform fee income, which has lower cost of sales than product sales. The operating loss narrowed, but net loss improved only modestly, partly because a $576,417 non-cash loss was recorded on conversion of debt. Basic and diluted loss per share was $0.07, versus $0.15 in 2013.
At year-end, cash was $705,602; current assets were $1,218,316 and current liabilities $553,677, yielding working capital of $664,639. Total assets were $1,222,118. The balance sheet reported no short-term or related-party debt outstanding at year-end. Cash increased by $621,285, primarily supported by $1,685,861 of financing cash flow, including equity proceeds. No cash dividends were paid.
Changes, outlook, risks, and unusual items
- Common-stock and warrant financing brought in $1.2 million in late 2014; the filing also reports $375,000 raised through preferred stock, which subsequently converted to common stock. Shares outstanding rose to 31,269,160 at year-end.
- Management’s 2015 priorities were platform development, customer-base growth, and revenue growth. It estimated next-12-month cost of sales and general and administrative needs of about $2.65 million and said additional funding would be needed. No revenue or profitability guidance was provided.
- The company reported it had never been profitable and expected further losses. It said sales needed to approximately double at the then-current revenue and expense levels to break even. Financing was not committed; equity financing could dilute shareholders, and debt financing could add obligations.
- Key business risks include competition from much larger distributors, reliance on a small number of wholesalers and a buying group, third-party logistics dependence, pharmacy adoption and fulfillment challenges, and changes to state and federal pharmaceutical-distribution rules, including track-and-trace requirements.
- Disclosure controls and internal control over financial reporting were reported ineffective, with material weaknesses involving accounting/reporting policies, manual financial consolidation, staffing, segregation of duties, and review controls. The auditor expressed an opinion on the financial statements but did not opine on control effectiveness.
- Related-party matters include $104,655 of management wages owed at year-end and rent paid to an entity owned by the CEO. The filing reported no pending legal proceedings.
Important facts for investors to verify
- Confirm the issuer: the filing identifies Trxade Group, Inc., not Scienture Holdings, Inc.
- Reconcile reported equity: the balance sheet shows total shareholder equity of $668,441, while the statement of changes in equity shows $688,441.
- Review the revenue and cash-flow figures against the audited statements; narrative sections contain small differences from statement totals.
- Assess cash runway, the timing and terms of future financing, and whether the stated 2015 spending needs can be funded.
- Track customer and supplier retention, marketplace transaction growth, and the economics of platform versus wholesale revenue.
- Monitor remediation of the disclosed material weaknesses and compliance with pharmaceutical licensing and traceability rules.